MB
CRNX icon

MPM BioImpact’s Crinetics Pharmaceuticals CRNX Stock Holding History

MPM BioImpact’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-428,975
Closed -$12.3M – 43
2025
Q2 		$12.3M Sell
428,975
-202,989
-32% -$6.27M 2.14% 21
2025
Q1 		$21.2M Buy
631,964
+14,929
+2% +$558K 3.64% 9
2024
Q4 		$31.5M Buy
617,035
+91,190
+17% +$5.1M 4.48% 2
2024
Q3 		$26.9M Sell
525,845
-31,339
-6% -$1.62M 4.03% 5
2024
Q2 		$25M Buy
557,184
+76,596
+16% +$3.54M 3.88% 5
2024
Q1 		$22.5M Buy
480,588
+2,354
+0.5% +$92.1K 3.62% 7
2023
Q4 		$17M Sell
478,234
-819
-0.2% -$25.1K 3.98% 8
2023
Q3 		$14.2M Hold
479,053
– – 3.8% 9
2023
Q2 		$8.63M Buy
479,053
+118,661
+33% +$2.37M 1.74% 18
2023
Q1 		$5.79M Sell
360,392
-11,247
-3% -$208K 1.5% 19
2022
Q4 		$6.8M Buy
371,639
+6,929
+2% +$122K 1.76% 17
2022
Q3 		$7.16M Sell
364,710
-1,966
-0.5% -$40.1K 1.7% 16
2022
Q2 		$6.84M Hold
366,676
– – 1.9% 12
2022
Q1 		$8.05M Sell
366,676
-13,116
-3% -$265K 2.16% 13
2021
Q4 		$10.8M Buy
379,792
+81,400
+27% +$2.01M 1.97% 12
2021
Q3 		$6.28M Buy
+298,392
New +$6.24M 0.97% 22

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

MPM BioImpact's CRNX Position: Q3 2025 in Review

MPM BioImpact sold out of Crinetics Pharmaceuticals (CRNX) in Q3 2025, closing a stake of 428,975 shares — an estimated $12.3M sold.

MPM BioImpact first reported a position in CRNX in Q3 2021 and held it in 16 quarters. The position peaked at $31.5M in Q4 2024. 225 funds tracked by Wall St. Rank hold CRNX as of Q3 2025.

  • MPM BioImpact reported no remaining Crinetics Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • MPM BioImpact sold 428,975 Crinetics Pharmaceuticals shares in Q3 2025, an estimated $12.3M.
  • MPM BioImpact first reported a position in Crinetics Pharmaceuticals in Q3 2021 and held it in 16 quarters.
  • MPM BioImpact's Crinetics Pharmaceuticals position peaked at $31.5M in Q4 2024.
  • 225 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2025.

Based on MPM BioImpact's 13F filing for Q3 2025, filed 14 Nov 2025.